Every fifth patient suffered a high nutritional risk-Results of a prospective patient survey in an oncological outpatient center.
MUST-Score
malnutrition
nutritional counseling
nutritional medical needs
nutritional risk screening
oncology outpatients
Journal
Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
08
2022
accepted:
11
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Malnutrition in cancer patients often remains undetected and underestimated in clinical practice despite studies revealing prevalences from 20 to 70%. Therefore, this study aimed to identify patient groups exposed to an increased nutritional risk in a university oncological outpatient center. Between May 2017 and January 2018 we screened oncological patients there using the malnutrition universal screening tool (MUST). Qualitative data were collected by a questionnaire to learn about patients' individual information needs and changes in patients' diets and stressful personal nutrition restrictions. We included 311 patients with various cancers. 20.3% ( This study confirms that using the MUST score is a valid screening procedure to identify outpatients at risk of developing malnutrition. Here one in five was at high risk, but only 1% would have been detected by BMI alone. Therefore, an ongoing screening procedure with meaningful parameters should be urgently implemented into the clinical routine of cancer outpatients as recommended in international guidelines.
Identifiants
pubmed: 36386917
doi: 10.3389/fnut.2022.1033265
pmc: PMC9659884
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1033265Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Jendretzki, Henniger, Schiffmann, Wolz, Kollikowski, Meining, Einsele, Winkler and Löffler.
Déclaration de conflit d'intérêts
CL: Lecture fees: Celgene GmbH, Roche GmbH, Novartis Pharma GmbH, BMS GmbH & Co. KGaA, Mundipharma GmbH Co. KG, and Merck KGaA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JPEN J Parenter Enteral Nutr. 2014 Feb;38(2):196-204
pubmed: 24748626
Breast Cancer Res Treat. 2010 Oct;123(3):627-35
pubmed: 20571870
Br J Nutr. 2004 Nov;92(5):799-808
pubmed: 15533269
Clin Nutr. 2017 Oct;36(5):1187-1196
pubmed: 28689670
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Clin Nutr. 2008 Jun;27(3):340-9
pubmed: 18504063
Clin Nutr. 2009 Aug;28(4):445-54
pubmed: 19477052
Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9
pubmed: 29506228
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):207-217
pubmed: 30920778
Clin Nutr. 2016 Dec;35(6):1464-1471
pubmed: 27113120
Clin Nutr. 2006 Aug;25(4):563-72
pubmed: 16698132
Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
Dtsch Med Wochenschr. 2020 Jan;145(1):e1-e9
pubmed: 31858492
Br J Nutr. 2006 Feb;95(2):325-30
pubmed: 16469149
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
J Nutr Health Aging. 2009 Nov;13(9):782-8
pubmed: 19812868
Cancer. 2013 Apr 15;119(8):1528-36
pubmed: 23310947
Proc Nutr Soc. 2016 May;75(2):199-211
pubmed: 26786393
Med Oncol. 2017 May;34(5):72
pubmed: 28353094
Clin Nutr. 2003 Aug;22(4):415-21
pubmed: 12880610
Clin Nutr. 2019 Apr;38(2):644-651
pubmed: 29789167